CME Supplement

Dyspareunia Associated with Vulvovaginal Atrophy: Innovations in Counseling, Diagnosis, and Management

This activity is supported by an independent educational grant from AMAG Pharmaceuticals Inc.

 

In the United States, there are approximately 64 million women who are postmenopausal. Of these women, it is estimated that 50%—or more than 32 million— have symptoms of vulvovaginal atrophy (VVA) and/or dyspareunia (painful sexual intercourse). These two conditions, along with several others, are components of the Genitourinary Syndrome of Menopause (GSM).

This CME-designated journal supplement is comprised of three articles that provide information and strategies regarding best practices as to patient counseling, diagnosis, and treatment of VVA, and its associated dyspareunia. The goal is to provide women’s health clinicians the knowledge and tools they need to optimize the care they provide to their menopausal patients.

Click here to read the supplement.

To access the posttest and evaluation, visit:

https://omniaeducation.com/dyspareunia/

An early version of this supplement distributed at the 2018 American College of Obstetricians and Gynecologists Annual Clinical and Scientific Meetings incorrectly dated the second photo in Figure 9 on page S16 “8-4-2010”. This was later corrected to read “8-4-2011”.

Next Article:

   Comments ()